Marijuana-derived epilepsy-drug sales rise 25%, but GW Pharma stock plunges more than 12%
November 05, 2019 at 16:48 PM EST
Shares of GW Pharmaceuticals PLC sunk more than 12% in the extended session Tuesday, after the cannabinoid drug maker reported better-than-expected revenue from its flagship product, Epidiolex.
